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Takeaway messages from the article 
x SHPT is associated with adverse outcomes in CKD and dialysis patients 
x Optimum PTH level is unclear in pre-dialysis CKD and the recommended 
range is wide for dialysis patients. 
x Management of SHPT is largely pharmacological focussing on lowering PTH 
x PTH lowering treatment has not shown improved cardiovascular risk, 
fractures and mortality. 
  
Abstract 
Secondary hyperparathyroidism (SHPT) is a common complication of CKD and is 
part of the chronic kidney disease-mineral bone disorder (CKD-MBD). SHPT is 
associated with increased risk of fracture and mortality, thus SHPT control is 
recommended as kidney function declines.  Effective SHPT management becomes 
more difficult once skeletal and cardiovascular adverse effects associated with 
severe SHPT have become established. However, interventional studies to lower 
parathyroid hormone (PTH) have so far shown inconsistent results in improving 
patient-centred outcomes such as mortality, cardiovascular events and fracture. 
Pharmacological treatment effect on PTH level is also inconsistent between pre-
dialysis CKD and dialysis patients which adds to the complexity of SHPT 
management. This review aims to give an overview on the pathophysiology, 
pharmacological and non-pharmacological treatment for SHPT in CKD including 
some of the limitations of current therapeutic options. 
 
  
1. Introduction 
Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney 
disease (CKD), affecting almost all CKD patients by the time they reach end stage 
renal disease requiring dialysis. Biochemical (calcium, phosphate, parathyroid 
hormone [PTH] and vitamin D) and bone abnormalities (renal osteodystrophy) 
complicating advanced CKD and dialysis are associated with significant morbidity 
and mortality (1-6), probably due to greater risk of fracture and extra-skeletal 
calcification leading to cardiovascular disease (7-9). Severe SHPT in dialysis 
patients is associated with up to 20% increased mortality (4, 5) and dialysis patients 
also have up to four fold increase in fracture incidence compared to non-dialysis 
patients (10) due to impaired bone quality (11, 12). Vascular calcification is highly 
prevalent in CKD and is only weakly related to traditional risk factors of 
cardiovascular disease in the general population such as hypertension and 
hyperlipidaemia (13). In 2006, this triad of biochemical abnormalities in mineral 
metabolism, vascular calcification and renal osteodystrophy was described as 
chronic kidney disease-mineral bone disorder (CKD-MBD) by the Kidney Disease: 
Improving Global Outcomes (KDIGO) group (14).   
Interventional studies to lower PTH have so far shown inconsistent results in 
improving patient-centred outcomes such as mortality, cardiovascular events and 
fracture (15, 16). Furthermore, the healthcare cost associated with uncontrolled 
SHPT treatment have been estimated at an additional USD$5600 per patient 
annually (17). This review aims to give an overview on the pathophysiology, 
pharmacological and non-pharmacological treatment for SHPT in CKD including 
some of the limitations of current therapeutic options.  
 
2. Pathophysiology of SHPT in CKD  
High serum phosphate can directly increase PTH secretion by parathyroid gland (18) 
but SHPT onset in CKD often precedes high serum phosphate. Fibroblast growth 
factor-23 (FGF-23) is a phosphaturic hormone which is released through an as yet 
uncertain mechanism by osteocytes and osteoblasts. FGF-23 levels start to rise in 
early CKD stage 2 while serum phosphate, calcium and PTH are still within the 
normal range and bone mineral metabolism is considered to be normal (19, 20). 
FGF-23 maintains normal serum phosphate via two main mechanisms. Firstly, by 
binding to its co-receptor, klotho, in the distal tubule in the kidney (21) which down-
regulates the sodium-phosphate co-transporter in the proximal tubule resulting in 
reduced phosphate reabsorption and thereby, promotes phosphaturia (22). 
Secondly, FGF-23 affects the vitamin D pathway E\LQKLELWLQJĮ-hydroxylase activity 
in the kidney (22). At the same time, it increases the activity of 24-hydroxylase which 
metabolises 1,25-dihydroxy and 25-hydroxyvitamin D (23). The net effect is a 
reduction in total 1,25-dihydroxyvitamin D level which reduces calcium and 
phosphate absorption from the gut (see Figure 1).  Serum phosphate level is 
maintained in the normal range until the phosphaturic effect of FGF-23 is blunted 
due to declining nephron number with progressive CKD.  
The effect of high FGF-23 on vitamin D metabolism is detected by two other 
receptors on parathyroid gland, namely calcium sensing receptor (CaSR) and 
vitamin D receptor (VDR). Hypocalcaemia due to low 1,25-dihydroxyvitamin D is 
detected by CaSR leading to increased PTH gene expression and PTH release in 
order to restore normal serum calcium. Similarly, reduced 1,25-dihydroxyvitamin D 
levels are sensed by VDR, also stimulating PTH release. Persistent stimulation of 
parathyroid gland in CKD leads to diffuse (polyclonal) hyperplasia which transforms 
into nodular (monoclonal) hyperplasia (24). These monoclonal parathyroid cells have 
reduced expression of CaSR and VDR (25); thus, they have reduced sensitivity to 
the change in serum calcium and 1,25-dihydroxyvitamin D levels. PTH release 
becomes autonomous which often results in hypercalcaemia and is termed tertiary 
hyperparathyroidism.  
Elevated levels of FGF-23, often a 1000-fold higher than in healthy individuals, are 
found in dialysis patients. Experimental study in rats with normal kidney function or 
early CKD showed that high circulating FGF-23 lowers PTH secretion. However, 
there is downregulation of Klotho-FGFR1c receptor complex in parathyroid gland of 
rats with advanced CKD. Therefore, high level of FGF-23 failed to decrease PTH 
level (26). 
 
3. Management of SHPT in CKD 
An approach to managing SHPT is summarised in Figure 2. It is important to follow 
the trend in the rise/fall of PTH rather than the absolute value when deciding on 
treatment at any level of CKD. This is because PTH level is influenced by serum 
calcium, vitamin D level and circadian rhythm (27). Furthermore, variation in sample 
stability, accuracy of assay calibration, standardisation and antibody specificity 
contribute to the variability between assays (28, 29). The frequently used assays are 
the second generation assaysVRFDOOHGµLQWDFW¶ PTH (iPTH), which measure both the 
whole PTH (1-84) and PTH (7-84) molecules. 7KHWKLUGJHQHUDWLRQµZKROH¶37+
assays, which only measure PTH (1-84) molecule, are available but is not currently 
recommended for routine clinical use. The ratio of PTH (1-84)/ PTH (7-84) has been 
assessed in the context of discriminating renal osteodystrophy subtypes, for which 
the findings have been inconsistent (30-33). There is limited evidence for its role in 
predicting clinical outcomes such as mortality and cardiovascular events (34-36).  
The KDIGO CKD-MBD guideline recommends keeping the PTH level 2-9 times the 
upper limit of normal for the assay in dialysis patients (37) based on a number of 
bone biopsy studies which demonstrated that PTH poorly predicts underlying bone 
turnover within this range (38-40).Whilst a very low or very high PTH levels can 
predict low-turnover and high-turnover bone disease, PTH remains a poor marker of 
underlying bone histomorphometry within the target range. Alkaline phosphatase 
(ALP) may improve the sensitivity of PTH in predicting high/low bone turnover (41, 
42) and mortality in dialysis patients (43, 44). The guideline also recommended 
simultaneous measurement of total ALP although no clear management target was 
set. The optimum PTH level is unknown for pre-dialysis CKD patients but 
consistently rising levels above the upper limit of normal should prompt an 
assessment of bone mineral parameters.  
Hyperphosphataemia is usually found in CKD stage 5 or on dialysis; it worsens 
SHPT and is associated with increased morbidity and mortality (3, 4, 6, 45-47). An 
observational study in haemodialysis patients by Streja et al showed that the lowest 
mortality was associated with concurrently controlled PTH and phosphate levels (2).  
 
3.1 Dietary phosphate restriction 
Dietary phosphate restriction has been shown to reduce 24-hour urinary phosphate 
excretion resulting from reduction of dietary phosphate absorption (48). Two studies 
have compared strict dietary phosphate restriction (500-900mg of phosphate daily) 
against normal or high phosphate diet (1500-2500mg of phosphate daily). Firstly, a 
study by Burnett et al in healthy subjects showed that dietary phosphate restriction 
reduced urinary phosphate excretion, lowered serum phosphate and FGF-23 
although PTH level was unchanged (49). In contrast, a pilot study by Isakova et al in 
normophosphataemic CKD stage 3-4 showed that dietary phosphate restriction 
reduced urinary phosphate excretion but serum phosphate, PTH and FGF-23 
remained unchanged (48). Unchanged PTH level in both studies may be due to the 
short period of intervention and longer period may be required in CKD to show the 
true overall effect on phosphate balance, PTH and FGF-23 control. However, there 
is no interventional study to show that phosphate restriction improves clinical 
outcomes and it is widely accepted that dietary phosphate restriction is unlikely to be 
sustained and extreme protein restriction to lower dietary phosphate can also be 
harmful (50).  
 
3.2 Pharmacological 
 
3.2.1 Phosphate binders 
The main aim for using phosphate binders is to lower intestinal absorption of 
phosphate by binding with dietary phosphate in the gut; thus lowering serum 
phosphate which may indirectly attenuate worsening SHPT. Specific instruction and 
adherence on taking it before or with meals is crucial for its effectiveness. There is 
little doubt that all types of phosphate binders are effective in lowering serum 
phosphate in dialysis patients when compared to placebo as shown in the systematic 
review carried out by Navaneethan et al (51). PTH reduction has also been observed 
with the use of phosphate binders in dialysis patients in some studies (52-55).  
The KDIGO CKD-MBD guideline recommends using phosphate binders only in 
hyperphosphataemic pre-dialysis CKD (37). This is because the optimum PTH level 
and the benefit of using phosphate binders in moderate CKD who are 
normophosphataemic to control SHPT remain unclear. Block et al randomised 148 
patients with CKD stage 3-4 who had serum phosphate in the upper normal range 
(mean 4.2 mg/dl) to calcium acetate, lanthanum carbonate, sevelamer carbonate 
and placebo. Results showed that all the phosphate binders modestly reduced 
serum phosphate despite significant reduction in urinary phosphate when compared 
to placebo (56). PTH level was unchanged in the treated group but worsened in the 
placebo group whereas FGF-23 level was unchanged in both groups. The treated 
group had an improvement in their bone mineral density but there was worsening of 
coronary artery calcification when compared to placebo which raises the question on 
safety of using phosphate binders in moderate CKD patients. In contrast, another 
study found that the progression of vascular calcification in patients randomised to 
low phosphate diet were similar to those on calcium-based phosphate binder (57). 
Thus, treating SHPT in pre-dialysis CKD remains controversial. 
Calcium-based binders (acetate and carbonate) are cheap and in current practice, 
modest dose of calcium (<1.5 g of elemental calcium daily) is widely accepted. 
However, there have been concerns regarding calcium loading and the risk of extra-
skeletal calcification. This led to the development of non-calcium based binders, 
namely sevelamer (hydrochloride and carbonate) and lanthanum (carbonate). These 
non-calcium-based phosphate binders have not shown superior phosphate or PTH 
reduction compared to calcium-based phosphate binders in head-to-head studies 
(51, 58, 59) but the studies have also focussed on 3 other outcomes; incidence of 
hypercalcaemia, mortality (60) and progression of vascular calcification (52, 53, 56, 
61-63). Three systematic reviews have been published by Navaneethan et al (51) 
and Jamal et al (64, 65) with different conclusions on whether there is a survival 
benefit when using non-calcium-based compared to calcium-based phosphate 
binders. It is unlikely that a sufficiently large study will be done to resolve this 
question. 
Aluminium-based phosphate binder is inexpensive and effective. Concerns regarding 
aluminium toxicity led to almost complete discontinuation of its use in 1980s although 
the primary source of aluminium exposure at the time came from dialysis fluid rather 
than aluminium-based binder (66). Reverse osmosis and stringent testing of dialysis 
water have almost completely removed aluminium in current practice. Thus, 6-14% 
of dialysis patients in Australia, New Zealand, Germany, Italy and Spain use this 
binder, whereas its use in the UK is minimal (2%) and often short term (67). Regular 
monitoring of serum aluminium is required.  
A recently published phase 3 clinical trial of PA21 compound (sucroferric 
oxyhydroxide) showed comparable efficacy to sevelamer in dialysis patients and 
PTH was reduced in both groups but more so with PA21 (68). Its use has been 
approved in the United States and Europe in 2014. Small clinical trials of SBR759 
iron-based compound have also shown its safety and efficacy in phosphate lowering 
but its effect on PTH was inconsistent (69-71).  
 
3.2.2 Vitamin D 
Vitamin D deficiency is highly prevalent in CKD, haemodialysis and peritoneal 
dialysis patients (72-74) and is associated with increased mortality (75, 76). The 
KDIGO CKD-MBD guideline suggests that the level is measured in CKD stages 3-5 
and dialysis; and replaced if deficiency or insufficiency is detected (37). It is a weak 
recommendation given the lack of conclusive evidence on patient level outcome from 
randomised controlled trials (RCTs) although a number of large observational 
studies showed a survival benefit associated with vitamin D treatment in CKD and 
dialysis patients (46, 77-82). The dose of vitamin D that should be used is also 
unclear in the guideline, so the dose in our treatment algorithm (Figure 2) is based 
on our local guideline. 
Vitamin D replacement in CKD patients can cause increased gut absorption of 
calcium and phosphate (83, 84). Given the importance of lowering serum phosphate 
to control SHPT and the risk of vascular calcification with hypercalcaemia, vitamin D 
replacement may seem counter-productive. However, not all vitamin D trials have 
shown significant hypercalcaemia and hyperphosphataemia as one would expect 
(85-87), nonetheless, the development of hypercalcaemia requires vitamin D dose 
reduction or cessation.  
The broad term of vitamin D has caused a lot of confusion in terms of investigations 
and treatment. The 25-hydroxyvitamin D level is the metabolite routinely measured in 
clinical practice whilst 1,25-dihydroxyvitamin D is often measured in research setting 
only. Treatment options for vitamin D deficiency comes in several forms; either as 
vitamin D2 or D3, or in its native form or analogs. Vitamin D receptor activator or 
agonist (VDRA) describes the vitamin D compounds which directly activate VDR. 
VDR are polymorphic and most VDRAs are non-selective (calcitriol, alfacalcidol, and 
doxercalciferol) but the selective VDRA (paricalcitol) has the theoretical advantage of 
targeting the VDR on parathyroid gland with minimal effect on VDR elsewhere such 
as in the gut and bone. Table 1 lists the commonly used vitamin D preparations.  
 
3.2.2.1 Native vitamin D 
It was previously thought that CKD and dialysis patients should only be given 
alfacalcidol (1-alpha hydroxyvitamin D3) or doxercalciferol (1-alpha hydroxyvitamin 
D2) which will then undergo 25-hydroxylation in the liver to form the active 1,25-
dihydroxyvitamin D. However, other sites in the body, such as skin, lymph nodes and 
macrophages, also have 1Į-hydroxylation activity (88, 89). To confirm this, several 
studies have shown that native vitamin D3 (cholecalciferol) supplementation 
improves 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 levels in dialysis 
patients (85-87). PTH level was significantly reduced by 20-35% from baseline in two 
studies although there was no placebo group for comparison (85, 86). One RCT on 
42 haemodialysis patients over 15 weeks did not show significant change in PTH 
with cholecalciferol compared to placebo (87) whereas a more recent RCT on 43 
haemodialysis patients by Delanaye et al showed statistically significant reduction in 
PTH with cholecalciferol whilst PTH was increased in the placebo group over a one-
year period (90). An RCT using ergocalciferol (native vitamin D2) or placebo over 12 
weeks in 105 dialysis patients did not show any difference in PTH level between the 
groups (91). The difference in PTH lowering effect from these 3 RCTs using native 
vitamin D in dialysis patients may be due to the different study duration but it is worth 
noting that there were no significant changes in serum calcium and phosphate. 
Despite the beneficial effect of native vitamin D replacement in controlling SHPT in 
dialysis patients, the effect in pre-dialysis CKD is inconsistent. In a study of elderly 
women, where over half had CKD stage 3, calcium (1.2g elemental calcium) and 
800IU cholecalciferol supplementation resulted in >30% decrease in PTH compared 
to placebo (92). However, this study cannot differentiate the individual effect from 
either calcium or vitamin D supplementation. Two small RCTs in pre-dialysis CKD 
using cholecalciferol did not show significant reduction in PTH compared to placebo 
but both studies had short intervention and follow up periods (93, 94). Two 
observational studies assessing ergocalciferol in CKD stages 3-4 consistently 
showed significant PTH reduction by up to 20% in CKD stage 3 but not in the more 
advanced CKD stage 4 (95, 96).  
 
3.2.2.2 Non-selective VDRA 
The active 1,25-dihydroxyvitamin D3, calcitriol, is a non-selective VDRA. A 
retrospective study showed that oral calcitriol significantly lowered PTH in pre-
dialysis CKD but at the expense of higher risk of hypercalcaemia compared to non-
users (82). In the 1990s, intravenous (IV) calcitriol was recommended as an 
alternative to oral calcitriol in dialysis patients with SHPT. Thrice weekly IV calcitriol 
on haemodialysis significantly lowered PTH but majority of patients also developed 
hypercalcaemia (97). 
Vitamin D analogs are non-selective synthetic VDRA of vitamin D3 (alfacalcidol) or 
vitamin D2 (doxercalciferol). A study using alfacalcidol in 176 mild-moderate CKD for 
2 years showed attenuation of PTH rise compared to placebo, but with increased 
incidence of hypercalcaemia which was likely to be dose-dependent as it resolved 
with dose reduction (98). In contrast, two other studies using alfacalcidol in pre-
dialysis CKD showed a significant PTH reduction from baseline by 15-50% but no 
hypercalcaemia (99, 100). A number of small studies assessed different preparations 
and dosing schedules of alfacalcidol in dialysis patients (101-103) but none 
compared it with placebo. These studies consistently showed that alfacalcidol is 
equally effective in reducing PTH across all forms (oral or IV) and dosing schedule 
(intermittent or daily). Doxercalciferol showed >40% PTH reduction from baseline 
with no significant change in serum calcium or phosphate in CKD (104) and dialysis 
patients (105). In contrast, another 2 studies in dialysis patients showed similar PTH 
reduction but with elevation of serum calcium and phosphate with doxercalciferol 
(106, 107).  
 
3.2.2.3 Selective VDRA 
Paricalcitol, a selective synthetic VDRA, is effective in lowering PTH in CKD (108, 
109) and dialysis patients (110-112). Both RCTs in CKD stages 3-4 by Coyne et al 
(108) and the PRIMO study (109) showed that 85-90% of paricalcitol-treated group 
achieved >30% PTH reduction compared to only around 15% in the placebo group 
achieving the same endpoint. However, there was a significantly higher incidence of 
hypercalcaemia when compared to placebo in the PRIMO study but no difference 
was found in the Coyne et al study. This difference may be due to the different 
dosing regimens but it is hard to compare because only one study reported the 
average dose used throughout the study (108).  
A small head-to-head study in 66 dialysis patients demonstrated that paricalcitol was 
as effective as calcitriol in reducing PTH and had similar safety profile (111). An 
earlier direct comparison study using their respective IV forms, which also included a 
dose adjustment protocol, showed that paricalcitol may achieve quicker PTH 
reduction with less sustained hypercalcaemia compared to calcitriol (112). 
Furthermore, an observational study on 38,000 dialysis patients showed a survival 
advantage associated with paricalcitol use compared to calcitriol (113). Despite 
these favourable evidence for using paricalcitol, it is uncertain whether it is cost 
effective compared to non-selective VDRA which are much cheaper. An investigator-
led randomised crossover trial comparing IV paricalcitol with alfacalcidol over a 16-
week period in dialysis patients demonstrated equal effectiveness in PTH reduction 
whilst maintaining calcium and phosphate in the desired range for dialysis population 
(114).  
The IMPACT SHPT (Improved Management of iPTH with Paricalcitol-centred 
Therapy versus Cinacalcet Therapy with Low-dose Vitamin D in Haemodialysis 
Patients with Secondary Hyperparathyroidism) study was an open label study 
comparing paricalcitol to calcimimetic (cinacalcet) plus low dose vitamin D in 268 
dialysis patients over a 28-week period. The mean baseline iPTH in this study was 
around 500 pg/mL and the primary efficacy end point was the proportion of patients 
achieving iPTH value of 150-300 pg/mL from week 21 onwards. A greater proportion 
of patients achieved the primary end point in paricalcitol group compared to 
cinacalcet group (115, 116). However, FGF-23 level was increased significantly with 
paricalcitol which was likely due to the significant increase in serum phosphate. 
Around 8-17% of patients on paricalcitol developed hypercalcaemia whilst 14-26% of 
patients on cinacalcet developed hypocalcaemia. This study highlights the difficulty 
in reducing PTH with VDRA at the expense of rising serum phosphate and FGF-23, 
and furthermore, paricalcitol still causes significant rise in serum phosphate despite 
being a selective VDRA.  
 
3.2.3 Calcimimetics 
Calcimimetics increase the sensitivity of CaSR in parathyroid glands to extra cellular 
calcium concentrations, leading to a reduction in circulating PTH concentrations 
within 1±2 hours after dosing.  In the UK, cinacalcet is not part of routine treatment 
for SHPT largely due to cost (117). The National Institute of Health and Care 
Excellence (NICE) guideline recommends its use in patients with uncontrolled SHPT 
(iPTH >800pg/ml) refractory to standard therapy with normal or high adjusted serum 
calcium or in whom the risk of surgical parathyroidectomy outweighs the benefit 
(118). 
Phase 3 clinical study of cinacalcet in dialysis patients demonstrated its 
effectiveness in PTH reduction, safety and tolerability (119). Vitamin D is often used 
to counteract hypocalcaemia related to cinacalcet. Thus, the combination use of 
native vitamin D or its analogs with cinacalcet allows calcium, phosphate and PTH 
target levels to be achieved simultaneously and greater PTH reduction has been 
observed using this combination therapy compared to either agent alone (120, 121). 
The OPTIMA study was an open label study which used an algorithm-based 
adjustment of VDRAs during the dose titration of cinacalcet in patients with moderate 
to severe SHPT (iPTH 300 ± 800 pg/ml). The analysis suggested that VDRAs can be 
used in conjunction with cinacalcet in order to achieve greater PTH reduction but 
there is a trade-off with respect to higher serum phosphate and calcium relating to 
VDRA use (122). In addition to PTH reduction, the combination therapy also 
attenuated vascular calcification in moderate to severe SHPT as shown in the 
ADVANCE study (123).  
A pooled analysis of phase 3 clinical trials data suggested benefit of using cinacalcet 
on a number of important end points including parathyroidectomy rates, fracture, 
cardiovascular hospitalisation and quality of life (15). This led to the design of 
EVOLVE (Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events) 
trial, an ambitious RCT aimed at a primary composite end point comprising of time 
until death, myocardial infarction, hospitalization for unstable angina, heart failure, or 
peripheral vascular events (16). 3883 haemodialysis patients with moderate to 
severe SHPT (median iPTH of 693 pg/ml) were randomised to cinacalcet or placebo 
while continuing conventional therapy including phosphate binders and vitamin D 
analogs as required. After a follow up of up to 63 months, the unadjusted intention-
to-treat analysis showed a non-significant 7% reduction in primary outcome measure 
(i.e. a negative study).  However, in the prespecified subgroup analysis, a 30% 
reduction in primary outcome was IRXQGLQWKHROGHU\HDUVSDWLHQWV who also 
had more cardiovascular co-morbidities (124). Secondary end points analysis 
showed no difference in fracture rate but parathyroidectomy rate was half in the 
intervention group compared to that in the control group. Despite significantly higher 
adverse events of hypocalcaemia in the cinacalcet group, it did not seem to have 
adverse impact on fractures or cardiovascular mortality. 
Gastrointestinal symptoms such as nausea and vomiting are known side effects of 
oral cinacalcet which may be overcome by IV calcimimetics. IV velcalcetide or 
AMG416 is currently in phase 3 clinical trial in haemodialysis patients with SHPT. It 
is a novel, long-acting selective peptide agonist of the CaSR which has been well 
tolerated and has shown rapid and sustained PTH reduction after a single dose in 
haemodialysis patients (125). 
 
3.3 Surgical 
Parathyroidectomy is considered for patients with uncontrolled SHPT when 
pharmacological treatment options have been exhausted. Evidence of potential 
survival benefit after parathyroidectomy came from retrospective studies (77, 126, 
127) but one retrospective study suggested that patients with persistently very low 
PTH levels post-parathyroidectomy had a higher 5-year mortality (128). Furthermore, 
there is concern relating to bone turnover as parathyroidectomy is likely to turn high 
turnover bone disease to adynamic bone disease (129) which is also associated with 
worse vascular calcification (130). An improvement of around 10% in bone mineral 
density (BMD) at 6 months after parathyroidectomy was reported (131) but another 
study found only modest improvement in BMD at 5 years after parathyroidectomy 
although no patient suffered any fractures during the follow up period (132). An RCT 
to compare the benefit of parathyroidectomy versus pharmacological treatment in 
uncontrolled SHPT is unlikely to ever be carried out and with increasing age and co-
morbidities amongst dialysis patients, surgical parathyroidectomy is becoming rare. 
Parathyroidectomy may be largely replaced by pharmacological treatment in the 
future if the cost of calcimimetics is reduced. 
 
4. Summary 
SHPT is associated with adverse outcomes in CKD and dialysis patients, thus there 
is a recommendation to control SHPT as renal function declines. Effective SHPT 
management becomes more difficult once skeletal and cardiovascular adverse 
effects associated with severe SHPT are established. Interventional strategies 
largely comprise of dietary phosphate restriction and pharmacotherapy although it 
remains very difficult to extrapolate biochemical end point to meaningful patient-
centred outcomes. Management of SHPT in pre-dialysis CKD remains inconclusive, 
partly because optimum target PTH level is still unknown and there is such 
heterogeneity in PTH level and CKD stages between clinical trials. The wide PTH 
range in dialysis patients as recommended by the KDIGO CKD-MBD guideline is 
sensible given that PTH is a poor marker of bone turnover and quality. Future 
studies in controlling SHPT requires multiple pharmacological and non-
pharmacological approach reflecting real clinical practice, inclusion of patient-centred 
outcomes, and better assessment of bone and vascular calcification which are also 
part of CKD-MBD.  
 
  
Figure 1: Normal vitamin D metabolism and steps that are affected by high FGF-23 
in CKD. 
 
 
 
 
  
Ύ Ύ 
Vitamin D3 is made in the skin when 7-dehydrocholesterol (also known as pro-D3) is converted to pre-
D3 when the skin is exposed to sunlight ultraviolet B-ray. Pre-D3 forms isomers which then binds to 
vitamin D binding protein (DBP) which is present in the circulation. Vitamin D3 is also available from 
dietary source where it enters the circulation via the intestine and binds with DBP. Vitamin D then goes 
through hydroxylation in the liver to make 25-hydroxyvitamin D (calcidiol). The final hydroxylation occurs 
in proximal tubule of the kidney to produce the active form 1,25-hydroxyvitamin D (calcitriol). The 1,25-
dihydroxyvitamin D increases intestinal calcium and phosphate absorption and promotes bone 
mineralization. It also has functions in the regulation of immune system. Vitamin D is removed from the 
body via 24-hydoxylation of calcidiol or calcitriol which are principally excreted in the bile. Its water 
soluble metabolites can also be excreted in the urine. * indicates the steps that are affected by high 
FGF-23 in CKD. 
Figure 2: Treatment algorithm for secondary hyperparathyroidism (SHPT) in pre-
dialysis CKD and dialysis patients. 
 
Abbreviations: chronic kidney disease, CKD; parathyroid hormone, PTH; vitamin D receptor activator, 
VDRA. 
 
  
Table 1: The commonly used vitamin D in CKD and dialysis patients for controlling SHPT. 
Vitamin D PTH reduction Hypercalcaemia Note 
Cholecalciferol 
(25-hydroxyvitamin D3) 
Conflicting in CKD (93, 94) 
Yes in dialysis (85-87, 90) No 5HTXLUHVĮ-hydroxylation in extra-renal sites 
Ergocalciferol 
(25-hydroxyvitamin D2) 
Conflicting in CKD (95, 96) 
No in dialysis (91) No 5HTXLUHVĮ-hydroxylation in extra-renal sites 
Calcitriol 
(1,25-dihydroxyvitamin D3) 
Yes in CKD (82) 
Yes in dialysis (97) Yes Non-selective VDRA 
Alfacalcidol 
(1-alpha hydroxyvitamin D3) 
Yes in CKD (98-100) 
Yes in dialysis (101-103) Conflicting 
Non-selective VDRA 
Requires 25-hydroxylation in the liver 
Doxercalciferol 
(1-alpha hydroxyvitamin D2) 
Yes in CKD (104) 
Yes in dialysis (105-107) Conflicting 
Non-selective VDRA 
Requires 25-hydroxylation in the liver 
Paricalcitol 
(19-nor-1,25-dihydroxyvitamin D2) 
Yes in CKD (108, 109) 
Yes in dialysis (110-112, 
114-116) 
Yes Selective synthetic VDRA 
Abbreviations: chronic kidney disease, CKD; secondary hyperparathyroidism, SHPT; parathyroid hormone, PTH; vitamin D receptor activator, 
VDRA. 
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